Vai al contenuto
Global sound
The Bio Report

The Bio Report

Neutralizing Tumor Acidity to Improve Cancer Immunotherapy

· 38 min · Episodio 194

Note dell’episodio

Many cancer treatments fail not because immune cells can’t recognize a tumor, but because the hostile environment surrounding it can prevent them from doing their job. Dyve Biosciences is seeking to address that problem by targeting tumor acidity, which the company says can suppress T-cell activity, promote immune evasion, and contribute to resistance to checkpoint inhibitors and other therapies. Its solution is a transdermal drug-delivery platform designed to move a buffering agent through the skin and into systemic circulation. The company’s lead oncology candidate, DYV 800, is intended to raise extracellular tumor pH and thereby make the tumor microenvironment more hospitable to immune attack. Ryan Beal, CEO of Dyve Biosciences, discusses why the company sees acidity as an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing.

Sito web: thebioreport.podbean.com

In diretta, ultima ora: 9.382 brani su 4.364 stazioni in 121 paesi

Scopri il mondo attraverso la radio

Altri modi per scoprire (7)

Hai sentito qualcosa di bello? Salvalo, o aprilo subito in Spotify.

★ Artista della settimana Il brano che sale più in fretta in radio questa settimana
Il tuo brano qui? Da € 9 a settimana →
Radio 538 luisteren - Live!Popolare ora